Treating Acute Leukemias
in Latin America
Emerging and Practical Concepts and Controversies in Leukemias
Overview
In recent years, progress in the understanding of acute leukemias has led to novel therapies that are rapidly changing treatment paradigms. Aptitude Health developed the Global Leukemia Academy to help physicians who treat acute leukemias bridge the gap between innovation and implementation for patient care.
Date and Location
March 25–26, 2022, Virtual Meeting
Meeting Content
View the slides and watch the video of Day 1
Virtual Plenary Sessions
View the slides and watch the video of Day 2
Virtual Breakout: Adult Leukemia Patients
View the slides and watch the video of Day 2
Virtual Breakout: Pediatric ALL Patients
Faculty
Elias Jabbour, MD
MD Anderson Cancer Center,
USA
Naval Daver, MD
MD Anderson Cancer Center,
USA
María Sara Felice, MD, PhD
Hospital Garrahan, Buenos Aires, Argentina
Paola Omaña, MD
Central Military Hospital,
Colombia
Josep-Maria Ribera, MD, PhD
Catalan Institute of Oncology,
University Hospital Germans Trias i Pujol,
Spain
Eunice Wang, MD
Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
Oscar Gonzáles-Ramella
University of Guadalajara,
Mexico
Wellington Silva, MD
Hospital Regional de São José,
Brazil
Roberta Demichelis, MD
Instituto Nacional de Ciencias Médicas y Nutrición Salvador, Zubirán,
Mexico
Carlos Andrés Portilla, MD
Centro Médico Imbanaco, Hemato-Oncólogo Pediátrico,
Cali, Columbia
Rob Pieters, MD, PhD
Princess Máxima Center for Pediatric Oncology,
University of Utrecht, The Netherlands
Franco Locatelli, MD
University of Rome, IRCCS Ospedale Pediatrico, Bambino Gesù, Italy
Christina Peters, MD
St. Anna Children’s Hospital, Stem Cell Transplantation Unit, Vienna, Austria
Adriana Seber, MD, GRAACC
Federal University of Sao Paulo, San Paulo, Brazil
Sergio Giralt, MD, FACP, FASTCT
University of Texas MD Anderson Cancer Center, USA
Stephanie Dixon, MD, MPH
St. Jude Children’s Research Hospital (SJCRH), USA
|
Agenda |
This 2-day interactive virtual meeting with global experts will focus on the management of acute leukemia in various countries within the Latin America region. Day 1: Follow presentations, join a debate on sequencing CD19-targeted strategies (systemic therapies vs CAR T), and engage with the faculty in panel discussions on optimal treatment and patient access, and regional challenges across Latin America. Day 2: Join the pediatric or adult breakout session to learn about treatment strategies for newly diagnosed and relapsed/refractory leukemia patients and attend the patient case-based panel discussion on toxicity management. |
Day 1 – PLENARY SESSIONS Friday, March 25, 2022
Chair: Elias Jabbour, MD
16.00 – 20.00 CDT/GMT-6 (Central Daylight Time: Mexico City/Bogota Time)
17.00 – 21.00 EDT/GMT-5 (Eastern Daylight Time: Atlanta)
18.00 – 22.00 BRT/GMT-3 (Brasilia Time: Buenos Aires, Rio de Janeiro)
| Rio Time (UTC-3) | Topic | Presenter |
| 18.00 – 18.10 | Welcome and meeting overview; introduction to the voting system Educational ARS questions for the audience |
Elias Jabbour |
| 18.10 – 18.40 | Recent developments in acute leukemias Presentation |
Elias Jabbour |
| 18.40 – 19.00 | Review of prognostic value of MRD in acute leukemias | José Maria Ribera |
| 19:00 – 19.20 | Current and future role of transplantation in acute leukemias | Sergio Giralt |
| 19.20 – 19.50 | Leukemia board discussion • AYA ALL case plus discussion – Adriana Seber • AML case plus discussion – Paola Omaña |
Moderator: Elias Jabbour All faculty |
| 19.50 – 20.00 | Break | |
| 20.00 – 20.20 | Optimal management and treatment coordination of long-term toxicities in pediatric leukemias | Franco Locatelli |
| 20.20 – 20.40 | AYA ALL patients – what is the current treatment approach for this diverse patient population? Special considerations for adolescents and young adults | Rob Pieters |
| 20.40 – 21.10 | Debate on sequencing CD19-targeted approaches in ALL • Monoclonal antibodies and bispecifics first • CAR T first • Discussion and voting |
Moderator: Franco Locatelli Elias Jabbour José Maria Ribera All faculty |
| 21.10 – 21.30 | Genetic characterization and risk stratification of AML Therapeutic approaches in high-risk and older AML patients |
Eunice Wang |
| 21.30 – 21.50 | Therapeutic approaches in high-risk and older AML patients | Naval Daver |
| 21.50 – 22.00 | Session close | Elias Jabbour |
Day 2 – BREAKOUT: ADULT ALL PATIENTS Saturday, March 26, 2022
Chair: Elias Jabbour
8.00 – 11.00 CDT/GMT-6 (Central Daylight/Mexico City/Bogota Time)
9.00 – 12.00 EDT/GMT-5 (Eastern Daylight Time)
10.00 – 13.00 BRT/GMT-3 (Brasilia/Buenos Aires Time)
| Rio Time (UTC-3) | Topic | Presenter |
| 10.00 – 10.10 | Session opening • Educational ARS questions for the audience |
Elias Jabbour |
| 10.10 – 10.30 | Optimizing first-line therapy in adult and older ALL – integration of immunotherapy into frontline regimens • Presentation • Q&A |
Elias Jabbour |
| 10.30 – 10.50 | Current treatment options for relapsed ALL in adult and elderly patients • Presentation • Q&A |
José Maria Ribera |
| 10.50 – 11.20 | ALL case-based panel discussion • Case 1 – Paola Omaña • Case 2 – (TBC) • Discussion |
All faculty |
| 11.20 – 11.30 | Break | |
| 11.30 –11.35 | AML session open • Educational ARS questions for the audience |
Naval Daver |
| 11.35 – 11.55 | Personalized induction and maintenance approaches for AML • Presentation • Q&A |
Eunice Wang |
| 11.55 – 12.15 | Optimizing management of relapsed/refractory AML • Presentation • Q&A |
Naval Daver |
| 12.15 – 12.45 | AML case-based panel discussion • Case 1 (10 min) – Wellington Fernandes • Case 2 (10 min) – Roberta Demichelis • Discussion (10 min) – Panelists: Paola Omaña |
All faculty |
| 12.45 – 13.00 | Session close • Educational ARS questions for the audience |
Elias Jabbour and Naval Daver |
Day 2 – BREAKOUT: PEDIATRIC ALL PATIENTS Saturday, March 26, 2022
Chair: Franco Locatelli, MD
8.00 – 11.00 CDT/GMT-6 (Central Daylight/Mexico City/Bogota Time)
9.00 – 12.00 EDT/GMT-5 (Eastern Daylight Time)
10.00 – 13.00 BRT/GMT-3 (Brasilia/Buenos Aires Time)
| Rio Time (UTC-3) | Topic | Presenter |
| 10.00 – 10.10 | Session opening • Educational ARS questions for the audience |
Franco Locatelli |
| 10.10 – 10.25 | The use of MRD for risk stratification and therapy guidance in pediatric ALL • Presentation • Q&A |
Rob Pieters |
| 10.25 – 10.45 | First-line treatment of pediatric ALL • Presentation • Q&A |
Christina Peters |
| 10.45 – 11.20 | Current treatment options for relapsed ALL in children, including HSCTPresentation • Q&A |
Franco Locatelli |
| 11.20 – 11.50 | ALL case-based panel discussion • Case 1 – Oscar Gonzáles Ramella • Case 2 – Carlos Andres Portilla • Discussion – Panelists: Maria Sara Felice , Oscar Gonzáles Ramella , Adriana Seber , Carlos Andres Portilla |
All faculty |
| 11.50 – 12.00 | Break | |
| 12.00 – 12.20 | Current treatment options for pediatric AML | Rob Pieters |
| 12.20 – 12.50 | AML case-based panel discussion • Case 1 (10 min) –Maria Sara Felice • Case 2 (10 min) –Adriana Seber • Discussion (10 min) – Panelists: Maria Sara Felice, Oscar Gonzáles Ramella , Adriana Seber (TBC), Carlos Andres Portilla |
All faculty |
| 12.50 – 13.00 | Session close • Educational ARS questions for the audience |
Franco Locatelli |
